Kumar R, Singh SK, Singh S, Kumar A. Addressing cardio-metabolic risks in type 2 diabetes: evidence-based insights on efpeglenatide. Int J Basic Clin Pharmacol [Internet]. 2025 Jun. 24 [cited 2025 Oct. 23];14(4):565-82. Available from: https://www.ijbcp.com/index.php/ijbcp/article/view/5828